109666
It was approved on 17 June 2013 by the European Medicines Agency for use in patients with low - or intermediate-1 - risk myelodysplastic syndromes who have 5q - deletion syndrome but no other cytogenetic abnormalities and are dependent on red blood cell transfusions , for whom other treatment options have been found to be insufficient or inadequate .
 organization: European Medicines Agency
Given options, please tell me the categories of all the listed entity words.Output format is "type1: word1; type2: word2". 
Option: media, plant, vehicle, astronomical object, time, disease, animal, location, person, organization, mythical figure, food, biology, geographical phenomenon, instrument, event 
Text: {0} 
 Entities: European Medicines Agency 
Answer:
 organization: European Medicines Agency